<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05106400</url>
  </required_header>
  <id_info>
    <org_study_id>A21.1463</org_study_id>
    <nct_id>NCT05106400</nct_id>
  </id_info>
  <brief_title>Clinical Adhesion Study Between ZTlido 1.8% and Three Over-the-counter External Analgesic Lidocaine-containing Patches</brief_title>
  <official_title>Open-label, Randomized, Four-treatment, Four-sequence, Four-period, Crossover, Single-application Study Evaluating and Comparing Product Adhesion in Healthy Adult Subjects Using ZTlido 1.8% Versus Salonpas(Lidocaine Patch 4%), Aspercreme(Lidocaine Patch 4%) and IcyHot(Lidocaine 4% + Menthol 1% Patch)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scilex Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scilex Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to evaluate and compare the clinical adhesion performance of the ZTlido&#xD;
      (Lidocaine Topical System) 1.8% of Scilex Pharmaceuticals Inc. (Reference) versus Salonpas&#xD;
      (Lidocaine Patch 4%), Aspercreme (Lidocaine Patch 4%) and IcyHot (Lidocaine 4% + Menthol 1%&#xD;
      Patch), on the Mid to upper back while being worn for 12 hours in healthy adult human&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Actual">July 21, 2021</completion_date>
  <primary_completion_date type="Actual">July 21, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized to ZTlido (Lidocaine Topical System) 1.8% or Salonpas (Lidocaine Patch 4%) or Aspercreme (Lidocaine Patch 4%) or IcyHot (Lidocaine 4% + Menthol 1% Patch). Subjects will crossover to each treatment after a wash out period.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Percent adhesion</measure>
    <time_frame>0, 3, 6, 8, 10, and 12 hours</time_frame>
    <description>The adhesion performance (i.e., degree of lifting or detachment) is assessed by clinicians at each time point. The adhesion of Test Products 1, 2, and 3 (each over-the-counter external analgesic lidocaine-containing patch) are compared to the adhesion performance observed for the Reference Product.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 hours</time_frame>
    <description>The number of adverse events observed in each treatment will be used to assess the safety and tolerability of the four interventions</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ZTlido (Lidocaine Topical System) 1.8%</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Salonpas (Lidocaine Patch 4%)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspercreme (Lidocaine Patch 4%)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IcyHot (Lidocaine 4% + Menthol 1% Patch)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZTlido (Lidocaine Topical System) 1.8%</intervention_name>
    <description>1 ZTlido (Lidocaine Topical System) 1.8% is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours</description>
    <arm_group_label>ZTlido (Lidocaine Topical System) 1.8%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salonpas (Lidocaine Patch 4%)</intervention_name>
    <description>1 Salonpas (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours</description>
    <arm_group_label>Salonpas (Lidocaine Patch 4%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspercreme (Lidocaine Patch 4%)</intervention_name>
    <description>1 Aspercreme (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours</description>
    <arm_group_label>Aspercreme (Lidocaine Patch 4%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IcyHot (Lidocaine 4% + Menthol 1% Patch)</intervention_name>
    <description>1 IcyHot (Lidocaine 4% + Menthol 1% Patch) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours</description>
    <arm_group_label>IcyHot (Lidocaine 4% + Menthol 1% Patch)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, male and female subjects aged 18 years and older with a Body Mass Index (BMI)&#xD;
             range 18.0-32.49 kg/m2 inclusive (according to the formula of BMI = weight (kg) /&#xD;
             [height (m)2]).&#xD;
&#xD;
          -  Subjects who have no evidence of underlying disease during screening and check-in and&#xD;
             whose screening is performed within 28 days of check-in.&#xD;
&#xD;
          -  Subjects whose screening laboratory values are within normal limits or considered by&#xD;
             the physician or Principal Investigator to be of no clinical significance.&#xD;
&#xD;
          -  Absence of disease markers of HIV 1 &amp; 2, hepatitis B &amp; C virus.&#xD;
&#xD;
          -  Generally healthy as documented by the medical history, physical examination&#xD;
             (including but may not be limited to an evaluation of the cardiovascular,&#xD;
             gastrointestinal, respiratory, musculoskeletal and central nervous systems) and vital&#xD;
             sign assessments.&#xD;
&#xD;
          -  Generally healthy as documented by 12-lead electrocardiogram (ECG), and clinical&#xD;
             laboratory assessments.&#xD;
&#xD;
          -  Any abnormalities/deviations from the acceptable range of medical history, clinical&#xD;
             laboratory values, ECG and vitals, that might be considered clinically relevant by the&#xD;
             study physician or investigator will be evaluated as individual cases.&#xD;
&#xD;
          -  Subjects able to comply with study procedures, in the opinion of the Principal&#xD;
             Investigator.&#xD;
&#xD;
          -  Willing to give written consent and adhere to all the requirements of this protocol.&#xD;
&#xD;
          -  Female subjects of childbearing potential;&#xD;
&#xD;
          -  Non-pregnant and non-lactating females practicing medically acceptable forms of Birth&#xD;
             Control and willing to continue during the study.&#xD;
&#xD;
          -  Postmenopausal Female- Age &gt; 45 years and Amenorrhea for at least 1 year; or Bilateral&#xD;
             Oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6&#xD;
             months; or Total hysterectomy and an absence of bleeding for at least 3 months.&#xD;
&#xD;
          -  Male volunteers must practice protected sex throughout the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of allergy or known hypersensitivity to lidocaine, local anesthetics of the&#xD;
             amide type e.g., bupivacaine, etidocaine, mepivacaine and prilocaine or to any of the&#xD;
             components of formulation.Any major illness in the last three months or any&#xD;
             significant chronic medical illness.&#xD;
&#xD;
          -  Subjects with history of addiction, abuse, and misuse of any drug - as per physician&#xD;
             discretion.&#xD;
&#xD;
          -  Subjects with history of mental illness as per physician discretion.&#xD;
&#xD;
          -  Presence or history of a clinically significant disorder involving the cardiovascular,&#xD;
             respiratory, renal, hepatic, dermatologic, musculoskeletal, gastrointestinal,&#xD;
             immunologic, hematologic, endocrine or neurologic system(s) or psychiatric disease (as&#xD;
             determined by the Medical Investigator).&#xD;
&#xD;
          -  Participation in any clinical trial within 30 days prior to product application.&#xD;
&#xD;
          -  Subjects with inflamed or injured skin, such as active herpes zoster lesions, atopic&#xD;
             dermatitis or wounds where the product will be placed.&#xD;
&#xD;
          -  Presence of any skin condition such as scratches, cuts, scars, abrasions, excessive&#xD;
             hair, tattoos, moles, recently shaved skin, uneven skin texture, open sores, irritated&#xD;
             (redness, rash, or blisters, etc.) or excessively oily skin at the application areas&#xD;
             that may affect the application of the study product.&#xD;
&#xD;
          -  Use of make-up, creams, lotions, powders, or other topical products to the skin area&#xD;
             where the product will be placed, within 48 hours prior to product application.&#xD;
&#xD;
          -  Use of antihistamines at product application site within 72 hours prior to product&#xD;
             application.&#xD;
&#xD;
          -  Using antiarrhythmic drugs (such as tocainide and mexiletine) and local anesthetics&#xD;
             within 14 days prior to product application.&#xD;
&#xD;
          -  Radiation therapy within 3 weeks prior to product application&#xD;
&#xD;
          -  History of significant dermatologic cancers (e.g., melanoma, squamous cell carcinoma&#xD;
             etc.) except basal cell carcinomas that were superficial and did not involve the&#xD;
             investigative sites.&#xD;
&#xD;
          -  Use of nicotine containing products (including e-cigarettes, patches, gum, chewing&#xD;
             tobacco, cigars, etc.) within 30 days prior to patch application.&#xD;
&#xD;
          -  Positive results for drugs of abuse and alcohol breath analysis prior to product&#xD;
             application.&#xD;
&#xD;
          -  Female subjects:&#xD;
&#xD;
          -  Demonstrating a positive pregnancy screen&#xD;
&#xD;
          -  Who are currently breastfeeding&#xD;
&#xD;
          -  Use of hormone replacement therapy within three months prior to product application.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dmitri Lissin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AXIS Clinicals</name>
      <address>
        <city>Dilworth</city>
        <state>Minnesota</state>
        <zip>56529</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 11, 2021</study_first_submitted>
  <study_first_submitted_qc>October 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Adhesions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

